3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Triple Negative Breast Neoplasms
2
Ovarian Neoplasms
1
Mesothelioma
1
Melanoma
1
Leukemia, Myeloid, Acute
1
Leukemia, Myeloid
1
Leukemia
1
Carcinoma, Non-Small-Cell Lung
1
Adrenocortical Carcinoma
1
Interventions
Cyclophosphamide
52
Cytarabine
49
fludarabine phosphate
38
fludarabine
32
Filgrastim
30
Etoposide
23
Rituximab
19
Azacitidine
17
Whole-Body Irradiation
16
Tacrolimus
14
Peripheral Blood Stem Cell Transplantation
13
Granulocyte Colony-Stimulating Factor
13
Decitabine
13
Clofarabine
13
venetoclax
12
Melphalan
12
Antilymphocyte Serum
12
Mycophenolic Acid
11
Methotrexate
11
Radiotherapy
10
Mitoxantrone
10
Daunorubicin
10
Busulfan
10
sargramostim
9
aldesleukin
9
Vincristine
9
Sirolimus
9
Topotecan
8
Idarubicin
8
Dexamethasone
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Leukemia
×
IPI-549
×
Clear all
NCT07439211
2026-03-03
GAVEL
Dana-Farber Cancer Institute
Phase 1
Not yet recruiting
48 enrolled